Clinical Trials at Southern Urology in Lafayette, LA
What is clinical research? A clinical trial is a study that is carefully designed to answer specific questions about the safety and effectiveness of new medications, treatments, therapies or surgical techniques. At Urology America, we participate in trials of all these types. All advances in modern medicine are made through the process of clinical research.
Why participate in a study? Clinical trials offer real benefits to current and future patients. A study will often offer access to a new treatment option that is not currently available to the public. These new options are usually designed to address a specific short-coming in current medical practice, and thus they often appeal to patients. You will receive very detailed and specific care from the research team before and during the trial. In addition to potentially receiving the investigational treatment, you have the added benefit of contributing to the future of medicine.
Are trials safe? All medical treatments and choices, including clinical trials, involve risks. There are, however, layers of oversight to help keep patients safe. Clinical trial protocols are nearly always approved by the FDA and by an IRB (institutional review board) before being offered to patients. These are independent entities that help ensure patient safety. Patients on a trial are cared for by CRCs (clinical research coordinators) who are experts at trial conduct and patient care and will work closely with each patient. Investigators on the trial are physicians or providers whose ultimate responsibility is to ensure patient safety and provide attentive care for any issues that arise.
The Southern Urology Clinical Research Departments is now recruiting for the clinical trials listed below. If you’re interested in participating and want to learn more about enrollment criteria, contact our research team for more information:
Email: solivier@ssmsla.com
Phone: (337) 422-3770
ACTIVELY ENROLLING CLINICAL TRIALS
Bladder Cancer Trials
CG Oncology Protocol #PIVOT-006
A Phase 3, Randomized Study of Adjuvant Cretostimogene Grenadenorepvec versus Observation for the Treatment of Intermediate Risk Non-Muscle Invasive Bladder Cancer (IR_NMIBC) Following Transurethral Resection of Bladder Tumor (TURBT)
CG Oncology Protocol #CORE-008
A Phase 2, Multi-Arm, Multi-Cohort, Open-Label Study to Evaluate the Safety and Efficacy of Cretostimogene Grenadenorepvec in Participants with High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)
Protara Protocol TARA-002-101
Men and women, 18 and older, with a type of high-grade bladder cancer called carcinoma in-situ (or CIS) are needed for a 5-year treatment study. The treatment will be given directly into the bladder. You must not be allergic to penicillin. You are eligible if you have had previous treatments for your bladder cancer (such as BCG) or if you have not.
A Phase 1b/2, dose expansion, open-label study to evaluate safety and anti-tumor activity, of intravesical instillation of TARA-002 in adults with high-grade non-muscle invasive bladder cancer
UPCOMING BLADDER CANCER TRIALS
CG Oncology Protocol #BOND-003
A Phase 3 Study of Cretostimogene Grenadenorepvec in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG)
